...
首页> 外文期刊>Thoracic cancer. >Prognostic significance of AKR1B10 in patients with resected lung adenocarcinoma
【24h】

Prognostic significance of AKR1B10 in patients with resected lung adenocarcinoma

机译:AKR1B10在切除肺腺癌患者中的预后意义

获取原文

摘要

Background Aldo‐keto reductases (AKRs) modify carbonyl groups on aldehyde or ketones to form primary or secondary alcohols, which are then conjugated with sulfates or glucuronide for excretion. The AKR1B10 gene encodes a member of the AKR superfamily. Overexpression of AKR1B10 plays an important role in the tumorigenesis of lung cancer cells; however, the prognostic value of AKR1B10 expression in patients with lung adenocarcinoma has not been well demonstrated. Methods A total of 96 patients with resected lung adenocarcinoma were included in the study. AKR1B10 expression was determined by immunohistochemistry in tumor specimens. The prognostic value of AKR1B10 overexpression and its relationship with clinicopathological variables were investigated. Results AKR1B10 overexpression was identified in 22 (22.9%) of the 96 patients and tended to be significantly associated with N1 or N2 status ( P = 0.055). AKR1B10 overexpression was not a significant prognostic factor for overall survival ( P = 0.301) but was a significant prognostic factor for poor recurrence‐free survival ( P = 0.015). T status (T3 or T4 vs. T1 or T2; P = 0.020), N1 or N2 (vs. N0; P = 0.019), predominant pattern group (lepidic/acinar/papillary vs. micropapillary/solid; P = 0.023), and AKR1B10 overexpression ( P = 0.013) were significant prognostic factors for poor recurrence‐free survival in multivariate analysis. Conclusions AKR1B10 overexpression was a significant prognostic factor for poor recurrence‐free survival in patients with resected lung adenocarcinoma. This information is useful to stratify patients at high‐risk of recurrence after lung adenocarcinoma resection.
机译:背景醛酮还原酶(AKR)修饰醛或酮上的羰基以形成伯醇或仲醇,然后将其与硫酸盐或葡糖醛酸结合以排泄。 AKR1B10基因编码AKR超家族的成员。 AKR1B10的过表达在肺癌细胞的肿瘤发生中起重要作用。然而,AKR1B10表达在肺腺癌患者中的预后价值尚未得到充分证实。方法共纳入96例肺腺癌切除患者。 AKR1B10表达是通过免疫组织化学测定的肿瘤标本。研究了AKR1B10过表达的预后价值及其与临床病理变量的关系。结果96例患者中有22例(22.9%)识别出AKR1B10过表达,并倾向于与N1或N2状态显着相关(P = 0.055)。 AKR1B10过表达不是总体生存的重要预后因素(P = 0.301),但是不良的无复发生存的重要预后因素(P = 0.015)。 T状态(T3或T4与T1或T2; P = 0.020),N1或N2(与N0; P = 0.019),主要模式组(鳞状/针状/乳头状/微乳头/实心; P = 0.023),在多变量分析中,AKR1B10过表达和AKR1B10过表达(P = 0.013)是无复发生存率低的重要预后因素。结论AKR1B10过表达是切除肺腺癌患者无复发生存不良的重要预后因素。此信息有助于对肺腺癌切除术后高复发风险的患者进行分层。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号